Physician profile
Paul Willis
NPI 1104835180
$2,858.91
in general payments reported to CMS, 2019-2025
20 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $259 · 2021: $321 · 2022: $638 · 2023: $584 · 2024: $276 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,175.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $855.57 | 2019-2023 | Phasix Mesh |
| Medtronic, INC. | $483.73 | 2021-2025 | Endurant Iis |
| Medtronic Vascular, INC. | $330.69 | 2019 | |
| Philips North America LLC | $254.74 | 2022-2024 | (Br5) Peripheral Ivus |
| Tela Bio, INC. | $205.35 | 2023-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Ethicon US, LLC | $116.91 | 2021-2023 | Enseal, Monocryl, Echelon; Endopath |
| Conmed Corporation | $113.45 | 2022 | |
| Intuitive Surgical, INC. | $91.18 | 2020-2024 | |
| W. L. Gore & Associates, INC. | $75.86 | 2024 | Gore Viabahn Vbx Balloon Expandable Endo |
| Misonix INC | $48.34 | 2021 | |
| Organogenesis INC. | $46.52 | 2023-2024 | Puraply |
| Pacira Pharmaceuticals Incorporated | $45.60 | 2023 | Exparel, Zilretta, Iovera |
| Atricure, INC. | $37.21 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Vertex Pharmaceuticals Incorporated | $30.83 | 2025 | |
| Innocoll Pharmaceuticals Limited | $28.56 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $25.54 | 2022 | |
| Teleflex LLC | $20.61 | 2023 | Urolift |
| Takeda Pharmaceuticals U.S.A., INC. | $18.62 | 2022 | |
| Smith+Nephew, INC. | $15.87 | 2025 | Collagenase Santyl |
| Cumberland Pharmaceuticals, INC. | $13.73 | 2023 | Caldolor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.